COM:MONTEROSATX
Monte Rosa Therapeutics
- Stock
Last Close
8.35
22/11 21:00
Market Cap
238.49M
Beta: -
Volume Today
327
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | 480K - | 480K 0% | ||||
average payables | 5.13M - | 6.81M 32.77% | 7.21M 5.84% | 9.51M 31.86% | ||
average receivables | 3.83M - | 4.08M 6.60% | ||||
book value per share | -1.09 - | -2.24 105.64% | 13.90 720.11% | 5.75 58.66% | 3.49 39.31% | |
capex per share | -0.12 - | -0.16 25.45% | -0.39 149.69% | -0.27 29.77% | -0.37 35.51% | |
capex to depreciation | -19.24 - | -6.31 67.19% | -4.56 27.67% | -3.45 24.47% | -3.06 11.23% | |
capex to operating cash flow | 0.22 - | 0.15 34.48% | 0.16 11.52% | 0.14 14.83% | 0.43 211.33% | |
capex to revenue | ||||||
cash per share | 0.54 - | 1.92 256.60% | 13.84 621.63% | 5.57 59.80% | 4.52 18.75% | |
days of inventory on hand | ||||||
days payables outstanding | 654.21 - | |||||
days sales outstanding | ||||||
debt to assets | 0.07 - | 0.14 - | 0.15 10.41% | |||
debt to equity | -0.06 - | 0.17 - | 0.26 48.32% | |||
dividend yield | ||||||
earnings yield | -0.03 - | -0.08 130.65% | -0.14 79.89% | -0.29 106.56% | -0.47 60.12% | |
enterprise value | 230.79M - | 418.71M 81.42% | 164.43M 60.73% | 351.49M 113.76% | 208.33M 40.73% | |
enterprise value over ebitda | -30.18 - | -15.35 49.14% | -2.26 85.27% | -3.12 38.17% | -1.52 51.36% | |
ev to operating cash flow | -37.39 - | -18.16 51.42% | -2.77 84.75% | -3.80 37.23% | -4.76 25.12% | |
ev to sales | ||||||
free cash flow per share | -0.68 - | -1.22 79.36% | -2.76 127.21% | -2.23 19.27% | -1.22 45.20% | |
free cash flow yield | -0.03 - | -0.06 79.36% | -0.14 135.67% | -0.29 116.63% | -0.22 26.19% | |
graham net net | -1.55 - | -2.59 67.67% | 13.09 604.46% | 4.19 67.96% | 2.11 49.76% | |
graham number | 4.20 - | 9.15 117.79% | 30.00 227.95% | 16.92 43.59% | 14.38 15.06% | |
income quality | 0.80 - | 0.64 19.44% | 0.80 24.92% | 0.85 6.17% | 0.32 62.03% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | |
interest coverage | -7.99K - | -29.86 - | ||||
interest debt per share | 0.07 - | 1.07 - | 0.90 16.67% | |||
inventory turnover | ||||||
invested capital | -0.06 - | 0.17 - | 0.26 48.32% | |||
market cap | 236.04M - | 460.41M 95.06% | 510.50M 10.88% | 359.40M 29.60% | 290.39M 19.20% | |
net current asset value | -13.48M - | -54.52M 304.32% | 329.85M 705.07% | 204.91M 37.88% | 111.71M 45.48% | |
net debt to ebitda | 0.69 - | 1.53 122.87% | 4.76 211.28% | 0.07 98.52% | 0.60 751.28% | |
net income per share | -0.72 - | -1.66 130.65% | -2.88 73.43% | -2.22 23.02% | -2.63 18.88% | |
operating cash flow per share | -0.55 - | -1.06 91.46% | -2.37 123.90% | -1.96 17.55% | -0.85 56.47% | |
payables turnover | 0.56 - | |||||
receivables turnover | ||||||
research and ddevelopement to revenue | ||||||
return on tangible assets | -0.72 - | -0.73 1.08% | -0.20 73.11% | -0.31 55.59% | -0.45 45.83% | |
revenue per share | ||||||
roe | 0.66 - | 0.74 12.16% | -0.21 127.97% | -0.39 86.19% | -0.76 95.90% | |
roic | 0.73 - | 0.58 20.46% | -0.20 135.30% | -0.30 45.36% | -0.54 80.66% | |
sales general and administrative to revenue | ||||||
shareholders equity per share | -1.09 - | -2.24 105.64% | 13.90 720.11% | 5.75 58.66% | 3.49 39.31% | |
stock based compensation to revenue | ||||||
tangible asset value | -12.15M - | -48.73M 301.12% | 347.51M 813.17% | 271.41M 21.90% | 179.25M 33.96% | |
tangible book value per share | -1.09 - | -2.24 105.64% | 13.90 720.11% | 5.75 58.66% | 3.49 39.31% | |
working capital | 5.47M - | 14.32M 161.86% | 332.03M 2,219.28% | 250.32M 24.61% | 189.62M 24.25% |
All numbers in USD (except ratios and percentages)